A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Inclusion Criteria:

- Patient (male or female) ≥12 years of age

- ECOG (Eastern Cooperative Oncology Group) performance status ≤1

- Must have progressed following standard therapy, or for whom, in the opinion of the
Investigator, no effective standard therapy exists, is tolerated or appropriate.

- Patients must be willing and able to undergo study required biopsies.

- Presence of at least one measurable lesion according to RECIST v1.1.

- Documented MAPK pathway alteration

Exclusion Criteria:

- Prior treatment with ERK inhibitors.

- History or current evidence of retinal vein occlusion (RVO) or current risk factors
for RVO.

- Any medical condition that would, in the investigator's judgment, prevent the
patient's participation in the clinical study due to safety concerns or compliance
with clinical study procedures.

- Patients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days
prior to the start study treatment and for the duration of the study.

- Patients with malignant disease other than that being treated in the study.

- Clinically significant cardiac disease.

Other protocol-defined exclusion criteria may apply.